Horizon Therapeutics Plc - HZNP STOCK NEWS

Horizon Therapeutics plc (NASDAQ: HZNP) has released new data from a real-world analysis of TEPEZZA, the first FDA-approved treatment for Thyroid Eye Disease (TED), presented at the 91st Annual Meeting of the American Thyroid Association. The analysis revealed that only 4.9% of patients who completed an initial course of TEPEZZA required a second course within two years, indicating a low need for ongoing treatment. Additionally, survey results showed comparable mental health impacts among TED patients, irrespective of disease duration, highlighting the significant quality-of-life challenges posed by the condition.

Horizon Therapeutics (Nasdaq: HZNP) announced new data to be presented at the 91st Annual Meeting of the American Thyroid Association in Montreal from October 19-23. The data focuses on TEPEZZA, the FDA's first and only approved treatment for Thyroid Eye Disease (TED), providing insights on treatment patterns and patient outcomes. Presentations will cover topics such as steroid treatment patterns and the effects of treatment duration on TED patients. These findings aim to enhance physicians' understanding of TED.

Horizon Therapeutics has announced that new analyses of UPLIZNA will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from Oct. 26-28, 2022. UPLIZNA is the first FDA-approved anti-CD19 monoclonal antibody for treating adult patients with anti-AQP4 antibody positive NMOSD. Key presentations include efficacy comparisons and associations of B-cell subsets with disease activity. A symposium titled 'Step into the new era of NMOSD' will also be hosted on Oct. 27, highlighting advancements in NMOSD care.

Horizon Therapeutics (NASDAQ: HZNP) will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022. The management will host a live webcast at 8 a.m. Eastern Time to discuss the financial and operating outcomes. Investors can access the webcast via the company's investor relations website. A replay will be available two hours post-webcast. Horizon focuses on developing treatments for rare, autoimmune, and inflammatory diseases, emphasizing a commitment to impactful therapies.

Horizon Therapeutics plc presented new findings at AAO 2022 indicating extensive upregulation of IGF-1 and its pathways in patients with Thyroid Eye Disease (TED) across all disease stages. The study, led by UCLA's Shoaib Ugradar, reveals that low CAS patients experience ongoing disease activity, which can lead to debilitating symptoms. The research highlights IGF-1's role in both immune and ECM pathways, stressing the need for awareness among physicians regarding the chronic impacts of TED. Horizon aims to enhance treatment strategies based on this critical data.

Horizon Therapeutics plc (NASDAQ: HZNP) announced the completion of enrollment for its Phase 4 clinical trial (NCT04583735) to evaluate TEPEZZA as a treatment for Thyroid Eye Disease (TED) in patients with low Clinical Activity Scores. This randomized trial will assess efficacy, safety, and tolerability compared to placebo, with primary results expected in Q2 2023. TEPEZZA is the only FDA-approved treatment for TED, a rare autoimmune disease. The trial aims to demonstrate TEPEZZA's benefits for patients with low disease activity.

Horizon Therapeutics plc (NASDAQ: HZNP) is expanding its Horizon Scholars program to promote education equity and support diverse students in STEAM fields. The initiative now includes scholars from Meharry Medical College, aiming to alleviate student debt while providing mentorship and job opportunities. With a total of 40 scholars, the program fosters professional networking and experiential learning. Executives emphasize the importance of addressing education equity comprehensively, through both financial assistance and experiential opportunities to empower future STEAM leaders.

Horizon Therapeutics (HZNP) has announced the winner of its Horizon Prize, which is awarded to the EB Research Partnership for their Patient-Driven Data Platform aimed at enhancing the quality of life for Epidermolysis Bullosa (EB) patients. The organization will receive $150,000 in funding to develop a centralized platform that facilitates collaboration among patients, physicians, and researchers. This initiative aims to address the complexities faced by EB patients, known as 'Butterfly Children,' who suffer from severe skin conditions with no current treatment options.